Equillium, Inc. (EQ): Price and Financial Metrics


Equillium, Inc. (EQ)

Today's Latest Price: $3.19 USD

0.12 (-3.63%)

Updated Jul 10 4:00pm

Add EQ to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

EQ Daily Price Range
EQ 52-Week Price Range

EQ Stock Price Chart Technical Analysis Charts


EQ Price/Volume Stats

Current price $3.19 52-week high $5.79
Prev. close $3.32 52-week low $2.20
Day low $3.02 Volume 48,232
Day high $3.43 Avg. volume 31,733
50-day MA $2.95 Dividend yield N/A
200-day MA $3.61 Market Cap 56.41M

Equillium, Inc. (EQ) Company Bio


Equillium Inc. is leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is based in La Jolla, California.


EQ Latest News Stream


Event/TimeNews Detail
Loading, please wait...

EQ Latest Social Stream


Loading social stream, please wait...

View Full EQ Social Stream

Latest EQ News From Around the Web

Below are the latest news stories about Equillium Inc that investors may wish to consider to help them evaluate EQ as an investment opportunity.

Equillium Reports First Quarter 2020 Financial Results

LA JOLLA, Calif., May 13, 2020 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to.

Yahoo | May 13, 2020

Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference

LA JOLLA, Calif., May 07, 2020 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products.

Yahoo | May 7, 2020

Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

Equillium, Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Under the terms of the purchase agreement, and once a registration statement relating to the transaction has been declared effective, Equillium will have the right at its sole discretion, but not the obligation, to sell to LPC up to $15 million worth of shares of its common stock over the 36-month term of the agreement.

Yahoo | March 30, 2020

Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020.

Yahoo | March 26, 2020

Equillium Strengthens Leadership Team with Key Appointments

Equillium, Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced the appointment of Maple Fung, M.D., as vice president of clinical development and Matthew Ritter, Ph.D., as vice president of corporate development. Dr. Fung will be responsible for leading Equillium’s clinical development programs and integrating the Equillium’s development and translational research efforts to advance programs successfully through all phases of clinical development.

Yahoo | February 27, 2020

Read More 'EQ' Stories Here

EQ Price Returns

1-mo 18.59%
3-mo 25.59%
6-mo -31.55%
1-year -42.00%
3-year N/A
5-year N/A
YTD -5.62%
2019 -58.58%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7271 seconds.